Therapnea

Therapnea™ – A Game Changer in the Vastly Underserved Multi-Billion-Dollar Market for treating Obstructive Sleep Apnea (OSA) and Snoring.

The “Silent Killer”

Over 900 million people worldwide suffer from Obstructive Sleep Apnea (OSA) — of which 80% remain undiagnosed and untreated. That’s twice as many as diabetes patients, yet OSA remains largely ignored despite its devastating consequences.

OSA is linked to serious comorbidities such as:

Cardiovascular disease         Chronic Fatigue – Micro Sleep            Hypertension       Depression Stroke          Sexual Dysfunction, Libido Loss Diabetes       Premature Death

Untreated OSA increases mortality by 39% earning it the name “The Silent Killer”

Market Opportunity

Vast Untapped Demand

The global OSA therapy market is worth billions yet it remains critically underserved. The golden standard therapy is CPAP (Continues Positive Airway Pressure) using as air pump and facial mask.

Critical Gap in Care

Among those diagnosed moderate to severe, up to 50% are unable to adhere to CPAP therapy – leaving over 40 million diagnosed patients without effective treatment today.

Proven Economic Value

Treating OSA significantly reduces long-term healthcare costs by preventing chronic disease progression, lowering hospitalization rates and cardiovascular risks. Payers and health systems have every incentive to achieve higher therapy adherence.

Additional Market: Snoring

Therapnea™ also addresses the 100-200 million chronic snorers seeking alternatives – unlocking a second multi-billion-Dollar market.

 Therapnea Labs offers hope. We bring a real solution — one that is effective, tolerable.

The Advantages of Therapnea™ Technology and Devices

 1. Breakthrough Technology for Moderate to Severe OSA

Our advanced, proprietary solution addresses the ~50% of the market that cannot tolerate CPAP and currently has no alternative solution. With Therapnea™, tens of millions of people can finally experience meaningful relief. The system most probably be Class II.

 2. Innovative Solution for Heavy Snoring

Snoring has long lacked an effective remedy. Our unique technology offers real relief to millions worldwide, filling a major gap in the sleep-health market. Most likely be OTC.

 3. Smart Devices with Rich Data Collection

Our devices monitor multiple parameters throughout the sleep and securely transmit this data to both the patient’s physician and our platform. This creates an unparalleled database on sleep disorders, supporting personalized care and ongoing innovation.

 4. Robust Global IP Portfolio

Therapnea Labs holds strong, granted patents across key markets, including the USA, Europe, China, Hong Kong, Japan, India, Russia, Israel and more — providing a formidable competitive moat.

 5. Clinically Proven Tolerability

Our proof-of-concept clinical study confirmed excellent patient acceptance. No gag reflex issues were observed, and the active device component — the stent — was well tolerated by all participants. A questionnaire done in a sleep lab in Israel showed 72% prefer traying Therapnea™ rather than CPAP

 6. Massive Market Potential & ROI

With OSA and Snoring representing multi-billion-dollar markets, Therapnea™ is positioned for exceptional growth and the potential to become the next health-tech unicorn. Major sales may be done on B2B basis.

 7. World-Class Team

Our “AAA” team combines deep expertise, proven experience, and unmatched motivation — the driving force behind our success.